Skip to main content
MedPathMedPath Home
Clinical Trials/NCT04686760
NCT04686760
Completed
Not Applicable

Efficacy of Inhaled Nitroglycerin in Moderate to Severe Cases of COVID-19 Patients

University of Lahore1 site in 1 country278 target enrollmentStarted: November 15, 2020Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsCorona Virus Infection
InterventionsNitroglycerin

Overview

Phase
Not Applicable
Status
Completed
Sponsor
University of Lahore
Enrollment
278
Locations
1
Primary Endpoint
ratio of partial pressure of oxygen in arterial blood to fraction of inhaled oxygen
OverviewStudy DesignEligibility CriteriaArms & InterventionsOutcomesInvestigatorsSitesRecords & IdentifiersSimilar Trials

Overview

Brief Summary

In current analysis moderate to severely ill Covid-19 infected patients will be nebulized with nitroglycerin, and they will be compared with the standard nebulization

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
None

Eligibility Criteria

Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Diagnosed admitted cases of Covid-19 degree of illness should be moderate to severe both male and female every age group

Exclusion Criteria

  • •allergic to nitroglycerin sudden drop in blood pressure not given consent

Arms & Interventions

Nitroglycerin solution

Experimental

Intervention: Nitroglycerin (Drug)

Outcomes

Primary Outcomes

ratio of partial pressure of oxygen in arterial blood to fraction of inhaled oxygen

Time Frame: 5-7 days

Oxygen demand

Time Frame: 5-7 days

Secondary Outcomes

  • Duration of hospital stay(15 days)

Investigators

Sponsor
University of Lahore
Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Muhammad Mansoor Hafeez

Doctor

University of Lahore

Study Sites (1)

Loading locations...

Similar Trials

Completed
Phase 2
Nitric Oxide Gas Inhalation in Severe Acute Respiratory Syndrome in COVID-19SARS (Severe Acute Respiratory Syndrome)Coronavirus
NCT04306393Massachusetts General Hospital200
Completed
Phase 1
High Dose Inhaled Nitric Oxide for COVID-19 (ICU Patients)COVID-19
NCT04383002University Health Network, Toronto21
Withdrawn
Phase 2
Nitric Oxide Gas Inhalation for Severe Acute Respiratory Syndrome in COVID-19.Coronavirus Covid-19 Infection Variant OmicronSARS (Severe Acute Respiratory Syndrome)
NCT04290871Xijing Hospital
Not yet recruiting
Phase 2
Effect of Inhaled Nitric Oxide for the treatment of COVID-19
RBR-8nfx26Pontifícia Universidade Católica do Rio Grande do Sul - PUCRS
Terminated
Phase 2
Nitric Oxide Inhalation Therapy for COVID-19 Infections in the EDCOVID19
NCT04338828Massachusetts General Hospital47